Pneumococcal conjugate vaccines (PCV) have significantly reduced the burden of invasive (IPD) and non-invasive pneumococcal disease, globally. In Italy, after 11 years of PCV use (PCV7, 2007-PCV13, 2010, we aimed to evaluate the future clinical and economic value of continuing the current PCV13 national immunization program (NIP) compared with a switch to PCV10. A decision-analytic forecasting model was adapted to estimate the value of both pediatric vaccination strategies over a 10 year time horizon. Given the limited serotype-specific data in > 5yo, we evaluated cost-effectiveness by first, assuming the serotype distribution is equivalent in all ages, and second, limiting the benefit to only 0-5yo. Serotype-specific IPD incidence data in 0-5yo from 5 regions (Emilia-Romagna, Lombardia, A. P. Bolzano, A. P. Trento, and Piemonte) were derived from the literature and applied to the total population. IPD, pneumonia and acute otitis media (AOM) incidences and direct costs were obtained from the literature and national databases. Observed age-and serotype-specific IPD trends from Italy were used to forecast future cases under continuous PCV13 use. Finland serotype trends were used to model clinical impact under PCV10. When including all ages, a PCV13 NIP would save an incremental 7,761 cases of IPD, 742,468 cases of AOM, 17,668 cases of pneumonia, and prevent 1,153 deaths, over a switch to PCV10. When limiting to children 0-5yo, a PCV13 NIP would save an incremental 964,131 cases of disease and prevent 177 deaths, over a switch to PCV10. In both scenarios, despite the additional vaccination cost, maintaining PCV13 would be highly cost-effective over PCV10 at E269 per QALY when including all ages and at E2,987 per QALY when limiting to children 0-5yo. Maintaining high uptake of a pediatric PCV13 program in Italy continues to be a cost-effective intervention and prevents the highest number of cases, deaths, and costs over a lower valent PCV vaccine.
Pneumococcal conjugate vaccines (PCV) have significantly reduced the burden of invasive (IPD) and non-invasive pneumococcal disease, globally. In Italy, after 11 years of PCV use (PCV7, 2007 -PCV13, 2010 , we aimed to evaluate the future clinical and economic value of continuing the current PCV13 national immunization program (NIP) compared with a switch to PCV10. A decision-analytic forecasting model was adapted to estimate the value of both pediatric vaccination strategies over a 10 year time horizon. Given the limited serotype-specific data in > 5yo, we evaluated cost-effectiveness by first, assuming the serotype distribution is equivalent in all ages, and second, limiting the benefit to only 0-5yo. Serotype-specific IPD incidence data in 0-5yo from 5 regions (Emilia-Romagna, Lombardia, A. P. Bolzano, A. P. Trento, and Piemonte) were derived from the literature and applied to the total population. IPD, pneumonia and acute otitis media (AOM) incidences and direct costs were obtained from the literature and national databases. Observed age-and serotype-specific IPD trends from Italy were used to forecast future cases under continuous PCV13 use. Finland serotype trends were used to model clinical impact under PCV10. When including all ages, a PCV13 NIP would save an incremental 7,761 cases of IPD, 742,468 cases of AOM, 17,668 cases of pneumonia, and prevent 1,153 deaths, over a switch to PCV10. When limiting to children 0-5yo, a PCV13 NIP would save an incremental 964,131 cases of disease and prevent 177 deaths, over a switch to PCV10. In both scenarios, despite the additional vaccination cost, maintaining PCV13 would be highly cost-effective over PCV10 at E269 per QALY when including all ages and at E2,987 per QALY when limiting to children 0-5yo. Maintaining high uptake of a pediatric PCV13 program in Italy continues to be a cost-effective intervention and prevents the highest number of cases, deaths, and costs over a lower valent PCV vaccine.
Key messages:
Maintaining PCV13 prevents the highest number of cases, deaths, and costs over a lower valent PCV vaccine.
Maintaining high uptake of a pediatric PCV13 program in Italy continues to be a cost-effective intervention. 
7.R. Innovations and knowledge translation

Background:
Project MOCHA (Models of Child Health Appraised) funded within Horizon 2020, aims at appraisal of the models of primary child health care in the EU and EEA. One of the objectives is to explore the European capacity to implement evidence-based child health policy. Insight is needed in effective strategies, target audience and format for communicating recommendations from the MOCHA project, to ensure effective implementation of evidence-based solutions.
Methods:
In order to obtain evidence, an online survey amongst stakeholders was performed in 2018. Stakeholders from 21 European countries, specialized in prevention, treatment and monitoring, and problem recognition, were asked about the most effective strategies, target audience and format for communicating recommendations, to ensure implementation of evidence-based solutions.
Results:
The answers from representatives of 15 countries were obtained. According to stakeholders, the most effective strategies for communicating recommendations about child health policy were traditional scientific channels of spreading the information, such as policy acts or impact of policy makers. However much significance was given to the media, which often determine what is visible to the public and politicians. The target audience consisted of professionals including e. g. decision makers or stakeholders and nonprofessionals such as parents, patients and their families. Stakeholders emphasised that the format of communicating recommendations should not be solely scientific-oriented but also available through the popular media.
Conclusions:
The strategy of communicating evidence-based results should be suited to the target audiences' profile. The message should be adapted to various groups of recipients, both professional and non-professionals. An essential role in communicating evidence-based recommendations is played by media.
Key messages:
The strategies of effective implementation of evidence-based solutions should be adapted to the target audience. The profile of target audience is changing, and requires variation in the channels of communication of evidencebased solutions from scientific-oriented to populationoriented.
Transfer of best practices for health promotion and NCDs prevention in EU countries
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Background:
The European Commission supports the efforts of EU countries to achieve the nine voluntary targets of the United Nations and the WHO and the Sustainable Developments, aiming to decrease premature mortality from non-communicable diseases (NCD) by one third. For DG SANTE, to identify existing good/best practices and transfer them is a main priority, in the process of health promotion and NCD prevention in the EU. Therefore, the Commission is supporting Member States, who are committed for changes, in transferring best practices from another EU country to their own country. Sharing experience and transferring best practices between EU countries would lead to benefits, such as global health improvement, decreased burden of diseases and cost-effectiveness of health systems and projects. However, to ensure an effective transfer of a best practice, a ''Best practice Transfer Plan'' must be developed. The main concept 11th European Public Health Conference: Poster walks
